Other languages Pulmatrix, Inc.

Equities

PULM

US74584P3010

Market Closed - Nasdaq Other stock markets 01:30:00 2024-07-03 pm EDT			5-day change	1st Jan Change
2.19 ^USD	+9.50%		+12.31%	+17.74%

May. 29	MannKind Agrees to Cross License Deal With Pulmatrix	MT
May. 17	Pulmatrix Files Up to $95 Million Mixed Shelf	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

MannKind Agrees to Cross License Deal With Pulmatrix	May. 29
Pulmatrix Files Up to $95 Million Mixed Shelf	May. 17
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled Dhe for Acute Migraine	May. 15
Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10
Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer	Mar. 13
Pulmatrix Explores Strategic Alternatives	Jan. 08
Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis	Jan. 08
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole	23-08-23
Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Sector Update: Health Care Stocks Easing Late Tuesday	23-07-11
Sector Update: Health Care Stocks Lower Tuesday Afternoon	23-07-11
Pulmatrix Seeks FDA Approval to Launch Phase 2 Trial of Investigational Drug for Acute Migraine Treatment; Shares Rise	23-07-11
Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine	23-07-11
Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12
Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30
Pulmatrix Doses First Patient in Phase 2b Asthma Trial	23-02-06
Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis in Subjects with Asthma	23-02-06
Pulmatrix Reports Top-Line Results From Acute Migraine Treatment	23-01-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Pulmatrix, Inc.

Equities

PULM

US74584P3010

Other languages

Filters